NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Major Shareholder Daniel C. Javitt Sells 33,018 Shares

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPGet Rating) major shareholder Daniel C. Javitt sold 33,018 shares of the firm’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $1.05, for a total value of $34,668.90. Following the completion of the sale, the insider now directly owns 9,656,964 shares in the company, valued at $10,139,812.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

NRx Pharmaceuticals Price Performance

Shares of NRXP opened at $1.14 on Monday. NRx Pharmaceuticals, Inc. has a one year low of $0.49 and a one year high of $10.39. The company has a 50-day simple moving average of $0.81 and a two-hundred day simple moving average of $0.78. The firm has a market capitalization of $77.11 million, a PE ratio of -2.07 and a beta of 0.70.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in NRx Pharmaceuticals by 1.9% in the first quarter. BlackRock Inc. now owns 525,493 shares of the company’s stock worth $1,287,000 after buying an additional 10,045 shares during the period. Bank of New York Mellon Corp purchased a new stake in NRx Pharmaceuticals in the first quarter worth about $25,000. Citigroup Inc. lifted its holdings in NRx Pharmaceuticals by 355.1% in the first quarter. Citigroup Inc. now owns 15,208 shares of the company’s stock worth $37,000 after buying an additional 11,866 shares during the period. Ursa Fund Management LLC purchased a new stake in NRx Pharmaceuticals in the first quarter worth about $37,000. Finally, Northern Trust Corp lifted its holdings in NRx Pharmaceuticals by 61.5% in the first quarter. Northern Trust Corp now owns 58,598 shares of the company’s stock worth $144,000 after buying an additional 22,322 shares during the period. 3.87% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets assumed coverage on NRx Pharmaceuticals in a research note on Wednesday, November 9th. They issued a “buy” rating and a $4.00 target price on the stock.

NRx Pharmaceuticals Company Profile

(Get Rating)

NRX Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Recommended Stories

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.